Mode
Text Size
Log in / Sign up

Mycobacterium avium subsp. paratuberculosis may contribute to Crohn's disease through complex pathogenic mechanismsBacteria May Play a Role in Crohn's Disease and More

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that MAP may contribute to Crohn's disease, but links to MS, T1DM, and ALS remain associative without proven causality.

This narrative review explores the role of Mycobacterium avium subsp. paratuberculosis (MAP) in several inflammatory and neurodegenerative conditions, including Crohn's disease, multiple sclerosis (MS), Type 1 diabetes mellitus (T1DM), and amyotrophic lateral sclerosis (ALS). The review synthesizes evidence regarding MAP's environmental distribution, strain genotyping, and potential pathogenic mechanisms.

Regarding Crohn's disease, the authors state that evidence implies MAP may contribute to the condition. For MS, T1DM, and ALS, the review notes that links remain associative without proven causality. The review details several pathogenic mechanisms for MAP, including breaching the intestinal barrier via FAP-mediated invasion, establishing intracellular persistence using PknG, RelA, and ESX-3, and subverting host immunity via M2 macrophage polarization and IL-10/IL-6.

A significant limitation noted is the extrapolation of virulence mechanisms from other mycobacterial species. Additionally, the review notes diagnostic limitations, specifically that PCR cannot distinguish viable from non-viable organisms. These findings provide a theoretical framework for potential prevention, diagnosis, and targeted intervention of MAP-associated disorders, though clinical evidence for causality in several conditions remains insufficient.

How this fits prior evidence

This narrative review addresses a gap in the understanding of environmental and pathogenic drivers of Crohn's disease. While previous coverage noted that ILC3-to-ILC1 transition is supported in Crohn's disease, this review adds a potential role for Mycobacterium avium subsp. paratuberculosis (MAP) in the disease's pathogenesis. It also addresses conditions mentioned in prior coverage, such as multiple sclerosis and Type 1 diabetes mellitus, though it notes that links to these conditions remain associative without proven causality.

This review looked at the role of a bacterium called Mycobacterium avium subsp. paratuberculosis, often called MAP. Scientists are studying how this germ interacts with the human body. The review found that evidence suggests MAP may contribute to Crohn's disease by breaking through the intestinal barrier and staying inside cells to avoid the immune system.

While the review also noted links between MAP and other conditions, such as multiple sclerosis, type 1 diabetes, and ALS, these links are only associations. This means the research does not prove that the bacteria cause those specific diseases. The study also highlighted that current testing methods cannot always tell if the bacteria are currently active or not.

Because this is a narrative review, the findings are theoretical. The research provides a framework for future ways to diagnose and treat these conditions. However, because the evidence is still being explored, these findings are not yet ready to change how doctors treat patients today.

What this means for you:
Evidence suggests a link between MAP bacteria and Crohn's disease, but links to other conditions are not proven.

Common questions

Is this bacterium known to cause Crohn's disease?

The review suggests that the bacterium MAP may contribute to Crohn's disease. It does this by breaking through the intestinal barrier and using specific mechanisms to stay inside cells and avoid the immune system. However, this is a theoretical framework and not a confirmed cause for every patient.

Does this mean the bacteria cause multiple sclerosis or type 1 diabetes?

The study found links between the bacteria and conditions like multiple sclerosis, type 1 diabetes, and ALS. However, these are only associations. The research does not prove that the bacteria cause these specific conditions, and more study is needed to understand the connection.

Are there any known side effects of treating this infection?

The provided research did not report on any specific treatments or the side effects of medications. Because this is a review of the bacteria's role in disease, it does not provide information on clinical treatments or safety data.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Mycobacterium avium subsp. paratuberculosis (MAP) is the primary causative agent of Johne’s disease (JD) in ruminants and bears potential public-health implications. Cumulative epidemiological and molecular evidence implies MAP may contribute to Crohn’s disease (CD), whereas its links to multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), and amyotrophic lateral sclerosis (ALS) remain associative without proven causality. This narrative review synthesizes MAP environmental distribution, strain genotyping, transmission routes, and multistage pathogenic mechanisms. MAP breaches the intestinal barrier via fibronectin attachment protein (FAP)-mediated invasion of microfold cells and establishes intracellular persistence within macrophages. It deploys virulence factors including protein kinase G (PknG) to inhibit phagosome–lysosome fusion, the stringent response regulator RelA for metabolic reprogramming, and the ESX-3 secretion system for iron acquisition, while subverting host immunity through M2 macrophage polarization and interleukin-10 (IL-10)/interleukin-6 (IL-6)-mediated anti-inflammatory responses, ultimately driving chronic granulomatous inflammation and tissue injury. We also critically assess diagnostic limitations—particularly the inability of polymerase chain reaction (PCR) to distinguish viable from non-viable organisms—and highlight major research challenges, including extrapolation of virulence mechanisms from other mycobacterial species. This work provides a theoretical framework for prevention, diagnosis, and targeted intervention of MAP-associated disorders.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.